Company Overview and News
Groupe ERAMET : augmentation à 1,75 dollar australien, prix final et définitif de l'Offre Publique d'Achat sur les actions de la société Mineral Deposits Limited (MDL)
VANCOUVER, British Columbia, May 23, 2018 (GLOBE NEWSWIRE) -- European Electric Metals Inc. (TSX-V:EVX) (“EVX” or “the Company”) is pleased to announce that it has signed an agreement to acquire an exploration application in Portugal for an advanced stage copper asset with historic production.
MNLDF RTPPF RIO RIO LUNMF RIO PWRMF RTNTF LUNCF LUN EVXXF MDL
Following its press release dated 27 April 2018, ERAMET today announces that its off-market takeover offer to acquire all of the issued shares in Mineral Deposits Limited (MDL) that it does not already own for A$1.46 cash per share (Offer) is now open for acceptance by MDL shareholders.
Mineral Deposits (MDL) chairman Nic Limb has responded negatively to Eramet’s unsolicited offer to acquire MDL for $287.5 million at $1.46/share, calling the offer “grossly inadequate” and urging shareholders to reject it.
Mineral Deposits Limited (ASX:MDL) is a leading ASX gainer after fielding a takeover offer from French-based, global mining company ERAMET SA (FRA:ER7).
MNLDF MDL ERA
ERAMET has today announced that it proposes to make an off-market takeover offer (Offer) to acquire all of the issued shares in Mineral Deposits Limited (MDL) that it does not already own for A$1.46 cash per share (Offer Price). This is an all-cash transaction that values the equity of MDL (on a fully diluted basis) at approximately A$291 million.
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to ASX:MDL / MINERAL DEPOSITS LIMITED on message board site Silicon Investor.
|CMDL : Any Thoughts?||AMDL Inc (OTC BB:AMDD) 18 month target $10|
|MDLI - Medicalogic, Inc.||AMDL Inc.|
|MDLK...Media Link International||MDL.V - 380% gain in two weeks! Why?|
|AMDL (BB: AMDDD)||MDL Information Systems (MDLI)|
|MDLI - TAKE A LOOK!!!|